Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raloxifene Hydrochloride

FDA-approved product (tablet, oral), marketed as Evista, Raloxifene Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Raloxifene Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Osteoporosis
  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raloxifene Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raloxifene Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women

    NCT01041092 · start 2004-06

    Registered record
    Registry ID
    NCT01041092
    Conditions
    Schizophrenia
    Interventions
    raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    2009-12
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionraloxifene
    PhasePhase 4
    Registry statusCompleted

  • 3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women

    NCT00310531 · start 2004-02

    Registered record
    Registry ID
    NCT00310531
    Conditions
    Osteopenia
    Interventions
    Menostar (Estradiol, BAY86-5435); Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-02
    Completion
    2007-06
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteopenia
    InterventionMenostar (Estradiol, BAY86-5435); Raloxifene
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

    NCT00163137 · start 2003-05

    Registered record
    Registry ID
    NCT00163137
    Conditions
    Osteoporosis
    Interventions
    lasofoxifene; raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-05
    Completion
    2005-10
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    Interventionlasofoxifene; raloxifene; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Estrogen Alternatives Study

    NCT00108238 · start 2003-04

    Registered record
    Registry ID
    NCT00108238
    Conditions
    Healthy
    Interventions
    Estradiol followed by progesterone; Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2006-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEstradiol followed by progesterone; Raloxifene
    PhasePhase 4
    Registry statusCompleted

  • Long Term Effects of Raloxifene Treatment on Bone Quality

    NCT00532428 · start 2003-04

    Registered record
    Registry ID
    NCT00532428
    Conditions
    Osteoporosis, Post-Menopausal
    Interventions
    Raloxifene; Raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2003-09
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Post-Menopausal
    InterventionRaloxifene; Raloxifene; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

    NCT00532246 · start 2003-03

    Registered record
    Registry ID
    NCT00532246
    Conditions
    Osteoporosis, Post-Menopausal
    Interventions
    raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-03
    Completion
    2003-08
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Post-Menopausal
    Interventionraloxifene; Placebo
    PhasePhase 4
    Registry statusCompleted

  • The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study

    NCT00206557 · start 2002-10

    Registered record
    Registry ID
    NCT00206557
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    Interventions
    Raloxifene; Estradiol/dyhydroprogestrone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-10
    Completion
    2007-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    InterventionRaloxifene; Estradiol/dyhydroprogestrone
    PhasePhase 2
    Registry statusCompleted

  • 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

    NCT00191425 · start 2002-08

    Registered record
    Registry ID
    NCT00191425
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    Teriparatide; Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-08
    Completion
    2005-11
    Enrolment
    810

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionTeriparatide; Raloxifene
    PhasePhase 4
    Registry statusCompleted

  • Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

    NCT00675688 · start 2002-04

    Registered record
    Registry ID
    NCT00675688
    Conditions
    Endometrial Hyperplasia; Osteoporosis
    Interventions
    Bazedoxifene/Conjugate Estrogens (CE); Raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04
    Completion
    2006-01
    Enrolment
    3,544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Hyperplasia; Osteoporosis
    InterventionBazedoxifene/Conjugate Estrogens (CE); Raloxifene; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Raloxifene and Rimostil for Perimenopause-Related Depression

    NCT00030147 · start 2002-02

    Registered record
    Registry ID
    NCT00030147
    Conditions
    Perimenopausal Depression; Depression
    Interventions
    Raloxifene; Rimostil; Transdermal Estradiol; Placebo skin patch and placebo tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2015-06
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerimenopausal Depression; Depression
    InterventionRaloxifene; Rimostil; Transdermal Estradiol; Placebo skin patch and placebo tablets
    PhasePhase 4
    Registry statusCompleted

  • Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

    NCT00035256 · start 2001-10

    Registered record
    Registry ID
    NCT00035256
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    teriparatide; raloxifene HCl; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-10
    Completion
    2005-07
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    Interventionteriparatide; raloxifene HCl; placebo
    PhasePhase 4
    Registry statusCompleted

  • Cognition in the Study of Tamoxifen and Raloxifene

    NCT00687102 · start 2001-10

    Registered record
    Registry ID
    NCT00687102
    Conditions
    Cognition; Aging
    Interventions
    tamoxifen; raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10
    Completion
    2008-03
    Enrolment
    1,498

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognition; Aging
    Interventiontamoxifen; raloxifene
    PhasePhase 3
    Registry statusCompleted

  • A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

    NCT00389740 · start 2001-04-02

    Registered record
    Registry ID
    NCT00389740
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    MK0217, /Duration of Treatment : 12 Months; Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-04-02
    Completion
    2003-01-16
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionMK0217, /Duration of Treatment : 12 Months; Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
    PhasePhase 3
    Registry statusCompleted

  • Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

    NCT00031811 · start 2001-03

    Registered record
    Registry ID
    NCT00031811
    Conditions
    Breast Cancer; Menopausal Symptoms; Osteoporosis
    Interventions
    raloxifene; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-03
    Completion
    2003-04
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Menopausal Symptoms; Osteoporosis
    Interventionraloxifene; quality-of-life assessment
    PhaseNot applicable
    Registry statusCompleted

  • Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

    NCT00031850 · start 2000-03

    Registered record
    Registry ID
    NCT00031850
    Conditions
    Breast Cancer
    Interventions
    goserelin acetate; raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-03
    Completion
    2007-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiongoserelin acetate; raloxifene
    PhaseNot applicable
    Registry statusCompleted